At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARTL Artelo Biosciences, Inc.
Market Closed 09-27 16:00:00 EDT
1.09
+0.01
+0.93%
盘后1.11
+0.02+1.83%
16:00 EDT
High1.13
Low1.09
Vol2.52K
Open1.09
D1 Closing1.08
Amplitude3.24%
Mkt Cap3.52M
Tradable Cap3.49M
Total Shares3.23M
T/O2.79K
T/O Rate0.08%
Tradable Shares3.20M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Optimistic Buy Rating for Artelo Biosciences Amidst Growing Focus on Cancer Cachexia Therapies
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.